Lasa Supergenerics Limited — Board Meeting, 14-11-2024: Outcome of Board Meeting

The Board of Directors of Lasa Supergenerics Limited has approved the financial results for the quarter and half-year ended September 30, 2024, during their recent meeting. A Limited Review Report from the Statutory Auditor for the same period was also considered. The company has noted that interest amounting to ₹0.43 crore on an ECB loan is currently under dispute, while certain dormant bank accounts and fixed deposits could not provide confirmation of their balances. Additionally, government incentives previously awarded are now recognized in the financial statements.